XX Rexxy Sxxaboxxtorxxs IXX Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: XX Rexxy Sxxaboxxtorxxs IXX Pharmaceutical Import Records from India — 2 Products, $200.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

XX Rexxy Sxxaboxxtorxxs IXX — Pharmaceutical Importer Profile (2026) | 2 Products, $200.0K Trade | TransData Nexus

XX Rexxy Sxxaboxxtorxxs IXX

Pharmaceutical Importer · United States · Respiratory & OTC Focus · $200.0K Total Trade · DGFT Verified

XX Rexxy Sxxaboxxtorxxs IXX is a pharmaceutical importer based in United States with a total trade value of $200.0K across 2 products in 2 therapeutic categories. Based on 4 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. XX Rexxy Sxxaboxxtorxxs IXX sources from 1 verified Indian supplier, with Dr Reddy S Laboratories Limited accounting for 100.0% of imports.

XX Rexxy Sxxaboxxtorxxs IXX — Import Portfolio & Supplier Network

XX Rexxy Sxxaboxxtorxxs IXX import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to XX Rexxy Sxxaboxxtorxxs IXX?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr Reddy S Laboratories Limited	$1.1M	23	100.0%

XX Rexxy Sxxaboxxtorxxs IXX sources from 1 verified Indian supplier across 9 distinct formulations. The sourcing is highly concentrated — Dr Reddy S Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Zenatane 40MG 30ct bstr CAPS	$500.0K	10
Fulvestrant 250 MG/5 ML	$100.0K	2
Sumatriptan INJ 6MG/.5ML 2x1s us autoinj	$100.0K	2
Thiamine INJ. 200MG/2ML 25's	$100.0K	2
Ephedrine sulfateinj USP 50MG/ML 25s	$100.0K	2
Atorvastatcaltabusp40mg(cryst	$100.0K	2
Sumatriptan INJ 6MG/.5ML 2x1s	$50.0K	1
Sodium nitroprusside INJ. 50MG/2ML	$50.0K	1
Glimepiride tablets USP 1MG (500's Pack)	$44.3K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ephedrine	Respiratory & OTC	$100.0K	2	0.4%	14
2	Fulvestrant	Advanced Oncology	$100.0K	2	0.7%	13

XX Rexxy Sxxaboxxtorxxs IXX imports 2 pharmaceutical products across 2 categories into United States totaling $200.0K.

XX Rexxy Sxxaboxxtorxxs IXX — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

XX Rexxy Sxxaboxxtorxxs IXX is a United States-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations. The company operates as a buyer, sourcing a diverse range of pharmaceutical products from international suppliers to meet the needs of the U.S. market. While specific details about its headquarters and parent company are not publicly disclosed, XX Rexxy Sxxaboxxtorxxs IXX plays a significant role in the U.S. pharmaceutical distribution network by facilitating the importation of essential medications.

In the period from 2022 to 2026, XX Rexxy Sxxaboxxtorxxs IXX imported a total of $200,000 worth of pharmaceutical products from India, comprising four shipments. The imported products spanned two therapeutic categories: Respiratory & OTC and Advanced Oncology, each accounting for 50% of the total imports. The top five products imported were Ephedrine and Fulvestrant, each valued at $100,000, representing 0.4% and 0.7% market share, respectively. Notably, the company's portfolio concentration is high, with the top five products constituting 100% of the imported goods.

2Distribution Network

Specific information regarding XX Rexxy Sxxaboxxtorxxs IXX's warehouse locations, logistics capabilities, and geographic coverage within the United States is not publicly available. However, as a pharmaceutical importer, the company likely collaborates with established logistics providers to ensure efficient distribution across the U.S. market. The reliance on a single supplier, DR REDDY S LABORATORIES LIMITED, suggests a streamlined supply chain, potentially facilitating focused logistics operations.

3Industry Role

XX Rexxy Sxxaboxxtorxxs IXX functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from international suppliers, particularly from India. By importing products such as Ephedrine and Fulvestrant, the company contributes to the availability of essential medications in the U.S. market, serving as a critical link between foreign manufacturers and domestic consumers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — XX Rexxy Sxxaboxxtorxxs IXX

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's sourcing strategy exhibits a high degree of concentration, with all imported products sourced exclusively from DR REDDY S LABORATORIES LIMITED. This single-source dependency may present risks, such as supply chain disruptions due to geopolitical events, regulatory changes, or operational issues within the supplier's facilities. However, the consistent volume of shipments and the substantial value of imports indicate a stable and well-established relationship between XX Rexxy Sxxaboxxtorxxs IXX and DR REDDY S LABORATORIES LIMITED. This suggests that the company has effectively mitigated potential risks through strategic partnership and thorough due diligence.

2Supply Chain Resilience

The resilience of XX Rexxy Sxxaboxxtorxxs IXX's supply chain is closely tied to the stability and reliability of DR REDDY S LABORATORIES LIMITED. Given the exclusive sourcing arrangement, the company may face challenges if alternative suppliers are not readily available. The limited number of formulations imported (nine unique formulations) further indicates a focused product strategy. To enhance supply chain resilience, XX Rexxy Sxxaboxxtorxxs IXX could consider diversifying its supplier base and increasing the variety of formulations sourced, thereby reducing dependency on a single supplier and mitigating potential risks.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure the safety, efficacy, and quality of drugs entering the U.S. market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval and importation. For Indian generics to be marketed in the U.S., they must undergo the FDA's New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the brand-name product.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. include obtaining an FDA registration for the manufacturing facility and ensuring that the products comply with FDA regulations. Good Manufacturing Practice (GMP) certification is essential, and the FDA recognizes certifications from reputable authorities such as the European Medicines Agency (EMA), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply XX Rexxy Sxxaboxxtorxxs IXX must ensure that their manufacturing facilities are FDA-registered and adhere to GMP standards recognized by the FDA.

XX Rexxy Sxxaboxxtorxxs IXX — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

XX Rexxy Sxxaboxxtorxxs IXX's focus on importing products in the Respiratory & OTC and Advanced Oncology therapeutic areas suggests a strategic alignment with market demand for these medications. The substantial import values of Ephedrine and Fulvestrant indicate a targeted approach to sourcing high-demand, high-value products. This strategy positions the company to meet specific patient needs and capitalize on market opportunities within these therapeutic categories.

2Sourcing Profile

XX Rexxy Sxxaboxxtorxxs IXX's sourcing strategy emphasizes the importation of generic drugs, particularly those in the Respiratory & OTC and Advanced Oncology categories. The exclusive sourcing from DR REDDY S LABORATORIES LIMITED reflects a preference for established suppliers with a proven track record. India's robust pharmaceutical manufacturing capabilities and adherence to international quality standards make it a key partner in XX Rexxy Sxxaboxxtorxxs IXX's procurement strategy.

3Market Positioning

Based on its product mix, XX Rexxy Sxxaboxxtorxxs IXX serves the U.S. market segment that includes retail pharmacies, hospitals, and potentially government tenders. The focus on high-demand therapeutic areas positions the company to meet the needs of various healthcare providers and patients, contributing to the overall pharmaceutical supply chain in the United States.

Seller's Guide — How to Become a Supplier to XX Rexxy Sxxaboxxtorxxs IXX

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to establish partnerships with XX Rexxy Sxxaboxxtorxxs IXX, particularly in the therapeutic areas of Respiratory & OTC and Advanced Oncology. By offering high-quality generic formulations that meet FDA standards, Indian exporters can fill gaps in XX Rexxy Sxxaboxxtorxxs IXX's current sourcing, potentially leading to expanded product offerings and increased market share.

2Requirements & Qualifications

Indian exporters seeking to supply XX Rexxy Sxxaboxxtorxxs IXX and the U.S. market must ensure that their manufacturing facilities are FDA-registered and comply with GMP standards recognized by the FDA. Products must undergo batch testing and stability studies to meet FDA requirements. Labeling must be in English and adhere to FDA guidelines, including serialization mandates.

3How to Approach

To establish a relationship with XX Rexxy Sxxaboxxtorxxs IXX, Indian exporters should initiate contact through formal channels, providing detailed product information, quality certifications, and evidence of FDA compliance. Participating in industry trade shows and networking events can also facilitate connections. Understanding the regulatory filing process and timelines for FDA approvals is crucial, as the process can be time-consuming and requires thorough documentation. Patience and persistence are essential, as building a successful partnership may take several months.

Frequently Asked Questions — XX Rexxy Sxxaboxxtorxxs IXX

What products does XX Rexxy Sxxaboxxtorxxs IXX import from India?

XX Rexxy Sxxaboxxtorxxs IXX imports 2 pharmaceutical products across 2 categories. Top imports: Ephedrine ($100.0K), Fulvestrant ($100.0K).

Who supplies pharmaceuticals to XX Rexxy Sxxaboxxtorxxs IXX from India?

XX Rexxy Sxxaboxxtorxxs IXX sources from 1 verified Indian suppliers. The primary supplier is Dr Reddy S Laboratories Limited (100.0% of imports, $1.1M).

What is XX Rexxy Sxxaboxxtorxxs IXX's total pharmaceutical import value?

XX Rexxy Sxxaboxxtorxxs IXX's total pharmaceutical import value from India is $200.0K, based on 4 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does XX Rexxy Sxxaboxxtorxxs IXX focus on?

XX Rexxy Sxxaboxxtorxxs IXX imports across 2 categories. The largest: Respiratory & OTC (50.0%), Advanced Oncology (50.0%).

Get Full XX Rexxy Sxxaboxxtorxxs IXX Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.